Home healthcare poised for rapid growth in Japan
This article was originally published in Clinica
Japan's medical equipment and supplies market has been recovering strongly since its stagnation in 1991, in line with the country's improving economic situation. The home healthcare market, currently valued at $750-800 million, is an area poised for particularly rapid growth, says a recent MDIS profile of Japan.
You may also be interested in...
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
In 2019, Mylan moved up to become the world’s leading generics, biosimilars and OTC player, according to Informa Pharma Intelligence’s latest global rankings. Sandoz has surpassed troubled Teva into second place but is set to surrender that position following the sale of its US solid-dose and dermatology business to India’s Aurobindo.